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POPULAR SCIENCE SUMMARY OF THE THESIS 
Two feared complications following anterior cruciate ligament (ACL) surgery are blood clots in 
the venous bloodstream and infections in the joint; venous thromboembolism and septic 
arthritis. Thromboembolism is most common in the lower leg, but it can propagate and enter 
into the lung circulation, a life-threatening condition in which cardiac arrest can occur. Septic 
arthritis is normally caused by bacteria. The infection can lead to damage to the cartilage, with 
poorer function in the affected joint. These serious complications are rare and difficult to study. 
Using register data, this thesis establishes their occurrence and presents novel risk factors. 
The ACL is a knee ligament with the function of stabilising the knee. It can be injured during 
sports participation, such as soccer or alpine skiing. Once injured, the ACL does not heal and 
entails an increased risk of osteoarthritis of the knee. The treatment is dependent on the patient’s 
need and the degree of knee instability, and consists of rehabilitation with or without surgery. 
The torn ACL is replaced during surgery using a tendon, which is most frequently harvested 
from the patient itself. 
The patient undergoing surgery is often young (mean age 27 years), active and working actively 
to return to the same activity level as before the injury. In Sweden, approximately 4,000 surgeries 
of the ACL are performed each year. 
This thesis is based on register data and includes more than 25,000 patients. By combining 
different sources of register data, it is possible to present a reliable number of the complications, 
as well as their risk factors. Using patient questionnaires, the outcome after surgery for patients 
with and without the complications can be measured. 
The studies in this thesis have shown that venous thromboembolism occurs in 0.4% of the 
surgeries, while the corresponding number for septic arthritis is 1.1%. Identified non-modifiable 
risk factors include, for venous thromboembolism, age at surgery and, for septic arthritis, sex. 
Modifiable risk factors for septic arthritis include the choice of tendon to replace the torn ACL, 
the choice of antibiotics administered at the time of surgery and the duration of surgery. The 
outcome for patients with postoperative venous thromboembolism and septic arthritis was 
poorer compared with patients without infection. 
With the knowledge of the presented risk factors in this thesis, it is possible to reduce the 






Background: Venous thromboembolism (VTE) and septic arthritis (SA) are two rare complications 
following anterior cruciate ligament reconstruction (ACLR). Due to their rare incidence, risk 
factors and outcome are difficult to analyse and the aims of this thesis are to improve knowledge 
in this area. 
Methods: All studies are register based. The study populations have been extracted from the 
Swedish Knee Ligament Register (SKLR) and have been linked to data from registers at the 
National Board of Health and Welfare to establish the incidence. A nationwide medical record 
review was performed to verify the events of SA. Risk factor analyses were made with data from 
both register sources. The subjective outcome was initially investigated with a non-response 
analysis of the SKLR, including a separate non-response questionnaire. Secondly, the subjective 
outcome for patients with VTE and SA was analysed based on data extracted from the SKLR. 
Finally, the risk of revision ACLR was investigated among patients with SA after primary ACLR. 
Results: The incidence of VTE and SA after ACLR was 0.4% and 1.1% respectively. The analyses 
of risk factors revealed that older age at surgery is the only independent risk factor for VTE after 
ACLR; while male sex, longer operating time, use of clindamycin instead of cloxacillin and a 
hamstring tendon autograft instead of a patellar tendon autograft are independent risk factors for 
SA after ACLR.  
The response rate for the subjective outcome is higher among female and older patients, with 
small differences in the outcome scores between respondents and non-respondents. 
The patients with SA report an inferior subjective outcome on all follow-up occasions and a 
poorer long-term outcome. The risk of revision ACLR is doubled among patients with SA after 
primary ACLR compared with patients without SA. 
Conclusion: This thesis demonstrates that an analysis of rare complications is possible using 
register data. Novel findings relating to risk factors for the studied complications, as well as novel 
findings on outcome data for patients with SA after primary ACLR, are presented. Knowledge 
about the risk factors can be used to modify and optimize perioperative routines in order to 
decrease the risk of serious complications and revision surgery, and to increase the subjective 
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1 LITERATURE REVIEW 
1.1 HISTORY OF ANTERIOR CRUCIATE LIGAMENT 
The anterior cruciate ligament (ACL) is a thoroughly studied ligament located in the central part 
of the knee. The ACL was first mentioned by Galen of Pergamon (131-201 AD), a greek 
physician who named the two cruciate ligaments based on their crossing appearance “ligamenta 
genu cruciata”. During the following 2000 years, the ACL was paid little documented attention. 
It is first in 1836 that the two brothers, Wilhelm and Eduard Weber, professors of Physics and 
Anatomy and Physiology in Leipzig, demonstrated the abnormal anterior-posterior movement of 
the tibia following sectioning of the ACL – the first described anterior drawer sign. In 1845, the 
french surgeon Amedeé Bonnet described three signs indicating an ACL rupture: “In patients 
who have note suffered a fracture, a snapping noise, haemarthrosis, and loss of knee 
function…”. He was also one of the first surgeons to describe the pivot-shift test: a subluxation 
is provoked in the ACL deficient knee. Another common test to diagnose the ACL injury is the 
Lachman test, which was described by the greek surgeon Georgios C. Noulis in 1875. However, 
the name Lachman orginates from the orthopaedic surgeon John Lachman who was active in 
Philadelphia, US, during the second half of the 20th century (1). 
  
 Figure 1. Anatomy of a right knee with patella removed. 
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1.2 ANATOMY OF THE KNEE 
The knee joint consist of four bones: the femur, tibia, fibula and patella. Several muscles with 
their tendon insertions, the menisci and ligaments interact to stabilise the knee. The central part 
of the knee has two cruciate ligaments, the ACL and the posterior cruciate ligament (PCL) (2) 
(Figure 1). 
The ACL is composed of type 1 collagen fibres and its blood supply derives mainly from the 
middle geniculate artery. The ligament is surrounded by synovial tissue which also contributes to 
the metabolism (3, 4). 
The ACL originates from the lateral femoral condyle notch in a ribbon-like structure with the 
lateral intercondylar ridge, as the anterior border, and the articular surface, as the posterior 
border (5). The insertion on the tibial eminence is duck foot-like or c-shaped with the bony 
landmarks “Parsons’s knob” anteriorly, the intertubercle ridge posteriorly and the medial 
intercondylar ridge medially (6). The largest cross-sectional area of the ACL is at the tibial 
insertion with 175 mm2, followed by the femoral insertion with 122 mm2, while the smallest area 
is found in the mid-substance with 40 mm2 (7). 
The main functions of the ACL are to balance and stabilise the knee in both the anterior-
posterior and the rotational plane (2). Different parts of the ACL act, with varying tension, 
during the range of motion of the knee, and were functionally divided into two bundles, the 
anteromedial (AM) and the posterolateral (PL), named after their insertions on the tibial side. 
The AM bundle is moderately lax when the knee is extended and tightens when the knee is 
flexed. The opposite applies to the PL bundle. In this way, the separate bundles counteract to 
stabilise the knee joint throughout the range of motion (8, 9). The length of the ACL varies from 
24 mm, in an unloaded 90-degree position of the knee joint, and 31 mm, when the knee is fully 
extended and an anterior tibial translation load is applied to the knee (7). 
1.3 EPIDEMIOLOGY 
The incidence of cruciate ligament injury in Sweden is 78/100,000 person-years (10). The 
corresponding number in the United States is uncertain, but it is estimated that around 200,000 
ACL injuries occur yearly (11). In the Swedish population, the mean age at which a cruciate 
ligament injury is sustained is 32 years, with 60% males. In younger patients, 11-20 years, females 
are injured to a greater extent than males (10). 
1.4 AETIOLOGY 
The ACL is exposed to a possible injury or tear during cutting and pivoting movements which 
can occur in daily life but more specifically during sports participation. In Sweden, the top three 
causes of ACL injury are soccer, alpine skiing and team handball (12).  
Most of the ACL injuries occur without contact with another person. The tear is considered to 
be caused by a deceleration combined with a change of direction, or following a jump where the 
landing takes place with the knee in or near full extension (13, 14). 
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The risk factors for an ACL injury are multifactorial and can be divided into environmental 
(weather, footwear), anatomical (BMI, femoral notch, knee recurvatum, joint laxity), hormonal 
(sex, menstrual status), neuromuscular (balance between muscles around the knee, trunk 
proprioception) and biomechanical (balance between the trunk and joints in the lower 
extremities) (15). 
1.5 DIAGNOSIS 
The diagnosis of an acute ACL injury is based on a combination of the patient’s history, which 
often includes some kind of popping sensation at the time of the injury, followed by a rapid 
effusion in the knee joint, and a thorough physical examination (16). The physical examination 
should include the Lachman and the pivot shift test. In a review, their respective sensitivity has 
been estimated at 85% and 30-40% and their specificity at 94% and 98% (17). Magnetic 
resonance imaging (MRI) can be used to diagnose the ACL tear, as well as concomitant injuries 
(18)(Figure 2). In a review compromising only prospective studies, the sensitivity and specificity 












The treatment of an ACL injury can be categorised into two entities; surgical and non-surgical. 
Surgery is recommended to patients with high knee stability demands in their occupation, or if 
the patient participate in a sport, with a high demand for knee stability. Surgery can sometimes 
also be indicated if the patient experience subjective instability in activities of daily living. Where 
the demands on knee stability are uncertain, an initial rehabilitation period, followed by an 
evaluation of function and subjective knee stability, can be advocated. If the patient has severe 
instability and/or episodes of “giving-way” following the rehabilitation period, surgery is usually 
recommended (16, 20, 21). By monitoring the patients during the rehabilitation period, it is 
possible to identify those in need for additional rehab or surgery, and to reduce the risk of 
associated injuries to the menisci and cartilage, which might lead to long-term poor results and 
osteoarthritis (22). 
Approximately half of all ACL injuries in Sweden are treated with surgery and the mean age of 






Figure 3. Illustration of a right knee with the arthroscopic camera through the 
anterolateral portal and the arthroscopic forceps through the anteromedial portal. 
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1.6.1 ACL repair 
The first described surgery was in 1895 when Sir Arthur Mayo-Robson performed an open ACL 
repair with silk sutures. The technique developed during the 20th century, but, in the end, it was 
finally abandoned due to poor results (1). In recent years, promising results have been reported 
and the technique is perhaps regaining its place, especially when the blood supply to the ACL is 
considered with only proximal tears being repaired. The technique often involves some kind of 
augmentation and it is thus considered more intricate to perform. However, it is still considered 
highly controversial with a lack of long-term outcome data (23, 24). 
1.6.2 ACL reconstruction 
1.6.2.1 History 
Parallel to ACL repair, the technique of ACL reconstruction (ACLR) evolved and, in 1917, 
Ernest William Hey Groves in Bristol performed the first ACLR using the fascia lata as a graft. 
The second graft to be used was the meniscus, which was followed by the use of patellar, 
quadriceps and hamstring tendons. These three tendon grafts are still in use today. Open surgery 
has currently been abandoned after the development of arthroscopic surgery. In 1912, the 
Danish surgeon, Severin Nordentoft, presented the use of an endoscopic technique to a joint – 
arthroscopy – and the first arthroscopically assisted ACLR was performed by David Dandy in 
Newmarket, UK, in 1980 (1, 25)(Figure 3). 
1.6.2.2 Surgical technique 
Different techniques for performing the arthroscopic drilling have evolved since 1980. Initially, 
the surgery was performed with the aim of placing the graft isometrically, often using a transtibial 
technique. Today, an ACLR is perfomerd by placing the graft anatomically, i.e. at the origin and 
insertion of the native ACL, and using three portals (26)(Figure 4a-c). 
1.6.2.3 Graft choice 
The choice of graft is an important aspect of ACLR. In Sweden, the most commonly used graft 
is a hamstring tendon autograft which consists of either the semitendinosus tendon together with 
the gracilis tendon, both doubled, or a quadrupled semitendinosus tendon (Figure 6). Another 
option is the patellar tendon autograft, which is harvested with bone blocks from both the patella 
and the tuberositas tibiae. With bone blocks, the healing and incorporation in the drilled tunnels 
is better than with soft-tissue grafts (27, 28). Soft-tissue grafts typically need 8-12 weeks to fully 
heal into the tunnels, followed by a remodelling process lasting at least 12 months (29-31). In 
Sweden, the patellar tendon autograft was the most commonly used graft until the beginning of 
the 21st century when hamstring autografts rapidly became more popular.  Today, hamstring 
autografts are used in 85% of the ACLRs in Sweden (21). The reasons for the popularity of the 
hamstring tendon autograft could be the relatively easy harvesting and low donor-site morbidity.  
Many studies report more donor-site morbidity, due mainly to anterior knee pain with patellar 
tendon autografts during the first two years after ACLR (32).   
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In studies comparing patellar with hamstring tendon autografts, the patient-reported outcome is 
similar or slightly better for the hamstring autograft in the short-term follow-up, with the 
potential drawback of an increased risk of revision ACLR compared with patellar tendon 
autografts (33, 34). Another proposed disadvantage of soft-tissue grafts is the risk of tunnel 
widening, which can complicate surgery if a revision is needed (35). 
The quadriceps tendon autograft is a third graft option, which is used less frequently but with 
increasing popularity. It can be harvested with or without bone blocks from the patella and is 
currently used in 6% of the ACLRs in Sweden (21, 36), increasing from low numbers. A recent 
prospective trial reported a similar patient-reported outcome and objective knee stability, when 
comparing quadriceps and hamstring tendon autografts, and the patients with quadriceps 
tendons had less donor-site morbidity but inferior quadriceps strength at the one-year follow-up 
(37).  
Finally, there is the option of using allografts with the benefits of no donor-site morbidity and 
reduced surgical time but the possible drawbacks of poorer healing, inferior mechanical 
properties and higher costs. The tissues that are used include the tibialis posterior, tibialis 
anterior, Achilles and patellar tendons. The allograft is recommended to be fresh frozen and not 
prepared with irradiation or a chemical process, which adversely can affect the graft properties 
(38). However, The use in Scandinavia is limited, with less than 1% in Sweden, whereas its use in 
the United States is around 20% (21, 39). 
  





Anatomically individualised ACLRs are a growing concept which, for example, includes graft 
choice based on the patient’s needs and requirements (40). However, when comparing the graft 
choice between countries, with 64% patellar tendon autografts in Norway and 8% in Sweden, it 
is obvious that there are differences in routines and traditions in the choice of graft between 
countries, that cannot be explained with graft choice due to patient related factors (21, 41). 
1.6.2.4 Epidemiology 
In 2019, 3,951 primary ACLRs were performed in Sweden (21). The corresponding number in 
the United States is more uncertain, but 129,836 ACLRs were reported in 2006 (11). The mean 
age of patients undergoing ACLR in Sweden is 27, while it is 29 in the United States. The 
proportion of female patients is 46% in Sweden and 42% in the United States (11, 21). 
1.7 PATIENT-REPORTED OUTCOME MEASURES 
Patient-reported outcome is one important way of measuring the effect of a given treatment. 
Normally, the patient-reported outcome measure (PROM) consists of a self-administered 
questionnaire. To best evaluate the effect of a treatment, it is recommended that a combination 
of a generic- and a disease-specific measurement should be used (42). 
1.7.1 European Quality of Life Five Dimension 
The European Quality of Life Five Dimension is a two-page questionnaire where the 
respondents describe their current health state. The first page includes five questions on mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. Each question has a three-
level scale ranging from “no problems” to “extreme/severe problems”. An index value from 0 
(worst) to 1 (best) is then calculated from the responses. The final page of the questionnaire 
includes a visual analogue scale (VAS) where the respondents grade their current state of health 
on a scale from 0-100, where 0 is the worst imaginable health state and 100 the best imaginable 
health state (43). 
1.7.2 Knee injury and Osteoarthritis Outcome Score 
In 1995, the Knee injury and Osteoarthritis Outcome Score (KOOS), was developed from the 
Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, to assess the 
outcome in patients with ACL injuries and osteoarthritis. It consists of five subscales: Symptoms, 
Pain, Activity of Daily Life (ADL), Sport and recreational function and Knee-related Quality of 
Life (QoL). Each subscale has several questions, to which the patient gives a score on a five-
point Likert scale1. The results are transformed to a 0-100 scale for each dimension, where 100 
represents no knee problems (44, 45). 
 
1 Likert scale – scale where the respondent answers a question on a five- or seven-point scale, named after the 
psychologist Rensis Likert 
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1.7.3 Minimal Important Change 
The minimal important change is the smallest change in a PROM score, which can measure a 
clinical difference (46). It has been suggested that a KOOS difference over time of 8-10 points 
indicates a clinical difference (47). In a more recent publication based on anchor questions, it is 
shown that the KOOS subscales of Sport and recreational function and QoL are preferred as 
primary outcomes with minimal important change values of 12.1 and 18.3 respectively. The 
subscales of Symptoms, Pain and ADL are not considered useful when analysing within-group 
change over time (48). 
1.7.4 Response rate 
One problem when collecting follow-up data is poor compliance and non-response. Historically, 
a response rate of 60% has been regarded as acceptable. However, this threshold has no 
scientific support and analysing the non-response group is instead recommended. If the non-
response group does not differ that much from the response group, a lower response rate could 
be acceptable and vice versa (49). 
  
 




Together with the other Nordic countries, Sweden has a long tradition of using registers. There 
are two categories of registers in Sweden; national public authority registers that are established 
via the Swedish Parliament and include all individuals without the opportunity to opt out. The 
health data registers at the National Board of Health and Welfare and the Population Register at 
Statistics Sweden are two examples. The other category is the national quality registers where the 
majority have been initiated by healthcare professionals. The quality registers include specific and 
more detailed information regarding the disease and/or treatment, normally together with a 
section with patient-reported outcome. In contrast to the public authority registers, the patient 
registers include an opportunity to opt out (50, 51).  
Two important terms when analysing a register are completeness and coverage. Completeness 
refers to the degree to which the register includes eligible patients among the target population. 
Coverage refers to the extent to which the number of units that are participating in the register 
among all the existing units perform data collection (50). 
1.8.1 The Personal Identification Number 
The personal identification number (PIN) is a unique identifier for each individual in the Swedish 
Population Register. It consists of date of birth, a three-digit birth code and a check digit and was 
introduced in its present form in 1967. Today, the Swedish Tax Agency is responsible for the 
administration of the PIN (52). The PIN makes analysis between different registers possible. 
1.8.2 The National Patient Register 
The National Patient Register (NPR) is administered by the Swedish National Board of Health 
and Welfare. The register was started in the 1960s and, since 2001, it has included all in- and out-
patient care in Sweden excluding primary health care. It consists of patient data (PIN, sex, age, 
place of residence), geographical data (hospital), administrative data (date of 
admission/discharge) and medical data (main and secondary diagnosis, procedures). Diagnoses 
are coded according to International Classification of Diseases (ICD) version 10 (53, 54). 
1.8.3 The Swedish Prescribed Drugs Register 
The Swedish Prescribed Drugs Register (SPDR) was started in July 2005 and includes all 
dispensed drugs. It consists of patient data (PIN, sex, age, place of residence), drug data (name, 
dose, dispensed amount) and administrative data (date of prescription and dispensing, profession 
and practice of the prescriber). The drugs are classified based on the Anatomical Therapeutic 
Chemical (ATC) classification system (55, 56). 
1.8.4 The Causes of Death Register 
The Causes of Death Register (CDR) was started in 1961 and includes all deaths and causes of 




1.8.5 The Swedish Knee Ligament Register 
The Swedish Knee Ligament Register (SKLR) is a quality register established in 2005 (Figure 5). 
It has completeness of more than 90% of all ACLRs in Sweden. The register consists of two 
parts: reports and perioperative observations by the surgeon, e.g. associated intra-articular 
injuries, type of graft, thrombo- and antibiotic prophylaxis administered and patient self-reported 
data. The patients register baseline data (BMI, smoking), the KOOS and the EQ-5D. The 
KOOS and EQ-5D are registered preoperatively and at one, two, five and 10 years 
postoperatively. The response rates in the SKLR in 2012 were 60% and 52% for the one- and 
two-year KOOS follow-ups, with even lower rates for the EQ-5D. In recent years, the response 
rate has declined (21, 58). 
1.9 COMPLICATIONS 
1.9.1 Venous thromboembolism 
Thrombosis is the occurrence of a clot in a blood vessel. It can be both arterial and venous, 
where the most common are clots that occur in arterial vessels which can cause a myocardial 
infarction or stroke. When the clot occurs in a vein, it is called a venous thromboembolism 
(VTE). Most commonly, a clot is formed in the calf as a deep vein thrombosis (DVT) which can 
either resolve spontaneously or propagate proximally (59). When the thrombosis enters the 
pulmonary circulatory system, it is called a pulmonary embolism (PE). The PE affects the cardiac 
workload to various degrees and, in the worst case, causes cardiac arrest and death (60). 
Another possible consequence of a DVT is the post-thrombotic syndrome, which is a chronic 
condition with a wide spectrum of symptoms from a swollen and painful extremity to severe leg 
ulcers. It is estimated that between 20-50% of the patients with a DVT develop post-thrombotic 
syndrome (61). 
1.9.1.1 Virchow’s Triad 
During the 19th century, Rudolf Virchow’s work on the way a venous thrombosis is formed 
resulted in the concept of “Virchow’s triad”, which is still applied today, where at least one in 
three underlying factors can cause a thrombosis (62, 63). 
D Abnormalities of the vessel wall. Trauma can cause an injury to the vessel wall, which 
causes a reduction in the anticoagulants produced by the endothelium (60, 64) and in 
turn causes a state of hypercoagulability. 
D Abnormalities of the blood constituents. Obesity, pregnancy, cancer and oral 
contraceptives are examples where the blood coagulation cascade per se is affected and 
causes a state of hypercoagulability (64).  
D Abnormalities of the blood flow. Reduced blood flow caused by stasis or immobility. 
Examples are long travel distances and postoperative immobilisation. The reduced 
circulation causes an imbalance between the factors in the anticoagulant pathway and the 





























































































Figure 5. The Swedish Knee Ligament Register annual reports from 2008 to 2019. 
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1.9.1.2 Incidence and risk factors 
In the general population, the incidence of VTE is estimated at 100 per 100,000 person-years 
and, of these, approximately 30% are PE (65). The mean age of VTE, in an adult population 
from northern Sweden (county of Västerbotten), is 73 years for women and 68 years for men 
(66). There are several known general risk factors for VTE, including age, genetic factors, cancer, 
immobilisation, trauma and surgery (65). In a ten-year report on 45,698 orthopaedic procedures 
from one institution, the overall incidence of VTE was 1.1%, with a distribution from 0.2% 
(upper extremity surgery) to 12% (internal fixation after pelvic fracture)(67). 
Following ACLR, the incidence of VTE varies with the type of study and whether asymptomatic 
and symptomatic VTE has been analysed. In register-based studies analysing symptomatic VTE, 
the incidence is reported as between 0.16% and 0.53% (68-70). In contrast, the incidence is 9% 
to 14% when asymptomatic VTE is analysed (71, 72). Most of the studies of VTE following 
ACLR are based on small cohorts with limited information on comorbidity and risk factors. 
However, some risk factors in the ACLR setting have been established; older age (69, 70, 73), 
tourniquet use > 120 minutes (74), multi-ligament reconstruction (70, 71), operating time > 90 
minutes (73) and female sex (73). 
  
 





To prevent postoperative VTE, recommendations from the American College of Chest 
Physicians on when to use thromboprophylaxis have been established. However, these 
recommendations only apply to arthroplasty and arthroscopic surgery in general and not 
specifically to patients undergoing ACLR (75). In a survey of Swedish ACL surgeons, 82% 
prescribed thromboprophylaxis when risk factors such as a history of thrombosis and oral 
contraceptives were present (76). 
1.9.2 Septic arthritis 
Septic arthritis (SA) is when a joint is infected by a microorganism, most commonly bacteria (77).  
In native joints, the most common path of transmission is hematogenous and it is thought that 
the microorganism enters the joint through the synovium which is vulnerable due to the lack of a 
protective basement membrane (78). The top three groups of bacteria causing native SA are 
Staphylococci, Streptococci and Gram-negative rods (79). Presumably, all joints can be affected 
by SA, and the most frequently involved joint among adults is the knee (78). In children, the hip 
joint is more frequently involved (80). 
The infected joint is damaged by three mechanisms; toxin produced by the bacteria, host 
inflammation response with the release of collagen-degrading enzymes and joint asphyxia caused 
by high intra-articular pressure (81). 
1.9.2.1 Incidence and risk factors 
The incidence of SA in the general population is 2-10/100,000 person-years (77, 80) and general 
risk factors for SA are pre-existing joint disease (rheumatoid arthritis, gout, osteoarthritis), 
diabetes mellitus, cirrhosis, end-stage renal disease and prednisone and other immune-
suppressive medications (78). 
Deep infection following total hip arthroplasty surgery ranges from 0.3% to 0.9% and the 
corresponding figure for total knee arthroplasty is 0.9% to 1.1% (82-84). Following ACLR, the 
rate of SA, in register-based cohorts, is reported as ranging from 0.28% to 1.0% (85, 86). Studies 
from single institutions show a higher rate from 0.58% to 1.8% (87, 88). The most common 
pathogen for SA after ACLR is coagulase-negative staphylococcus (89). 
The risk factors presented for SA after ACLR are diabetes mellitus (90), smoking (86), inpatient 
surgery (85) and hamstring autografts (88). However, bias can be attributed to theses analyses, as 
the cohorts are mostly of small size and the incidence rate is low. 
1.9.2.2 Treatment of SA following ACLR 
The initial treatment of SA following ACLR is to perform immediate arthroscopically assisted 
irrigation and debridement (I&D), with the retrieval of cultures as biopsy specimens, irrigation of 
the joint with 10-15 litres of saline solution and the initiation of empirical antibiotic treatment 
(91, 92). There are conflicting recommendations on whether to preserve or remove the graft (93) 
and in Sweden it is customary to preserve the graft (94). 
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1.9.2.3 Antibiotic prophylaxis 
To minimise the risk of postoperative infection, it is routine to use perioperative antibiotics in 
almost all kinds of orthopaedic surgery with implants, including ACLR (95, 96). The spectrum of 
antibiotic resistance differs between countries and, as a result, the choice of antibiotic 
prophylaxis differs accordingly (97, 98). In Sweden, the drug of choice is cloxacillin, with the 
alternative of clindamycin in the event of PC allergy (21). 
1.9.2.4 Prolonged antibiotic prophylaxis 
When the duration of the antibiotic prophylaxis is extended beyond 24 hours, it can be defined 
as prolonged antibiotic prophylaxis. However, there is no scientific support for using antibiotic 
prophylaxis for more than 24 hours (98, 99). 
1.10 OUTCOME AFTER ACLR 
Following ACLR, it is customary to analyse the subjective outcome by using PROMs. Factors 
associated with superior patient-reported outcomes following ACLR are age less than 18 (100), 
age of 40 years and older (101), male sex (102), not smoking (103, 104), receiving a hamstring 
tendon autograft (105) and having no concomitant injuries (106). 
Another option is to study the risk of revision ACLR, which has been shown to have an overall 
risk ranging from 2.1% to 7.7% in studies based on cohorts from 980 to 18,425 patients (107, 
108). 
1.10.1 Subjective outcome after ACLR complicated by VTE 
The patient-reported outcome after ACLR complicated by VTE has, previously, not been 
reported in the literature. The subjective outcome reported by patients who have undergone 
surgery for acute Achilles tendon rupture complicated by DVT is significantly lower as compared 
with those of patients without a DVT. However, the incidence of DVT after surgery for acute 
Achilles tendon rupture is considerably higher than the incidence of VTE after ACLR, and the 




1.10.2 Subjective outcome after ACLR complicated by SA 
The patient-reported outcome following ACLR complicated by SA has been reported in smaller 
series. In a review by Makhni, including 160 patients with infection and data on the Lysholm 
score*, no difference was shown between the infected group and the group without infection. In 
a sub-analysis comprising only 50 patients with infection and data on the International Knee 
Documentation Committee (IKDC)*, the infected group had significantly lower scores than the 
group without infection (110).  
1.10.3 Risk of revision after primary ACLR complicated by SA 
No studies have previously reported the risk of revision ACLR for patients who have undergone 


















* The Lysholm score and IKDC are examples of PROMs that include grading from an observer, which could 
introduce observer bias. 
 
 





2 RESEARCH AIMS 
The overall aim of this thesis was to describe the incidence of complications after ACLR, its risk 
factors and the impact on outcome. The specific objectives were: 
• To investigate the incidence of VTE and SA after ACLR 
• To investigate the risk factors for VTE and SA after ACLR 
• To analyse wheter non-respondents at the two-year follow-up in the SKLR differ from 
respondents, with respect to the baseline and outcome variables, and to analyse reasons 
for not responding 
• To describe the subjective outcome in patients who had a VTE 
• To describe the subjective outcome in patients who had SA after a primary ACLR 




3 MATERIALS AND METHODS 
In all four studies, the study populations have been retrieved from the SKLR. 
3.1 ANALYSIS OF INCIDENCE AND RISK FACTORS 
All primary and revision ACLRs from 2006 to 2013 were defined as the study population in the 
analysis of incidence and risk factors for VTE and SA, Studies II and III. The cohort was cross-
matched with the registers at the National Board of Health and Welfare; the National Patient 
Register, the Causes of Death Register and the Swedish Prescribed Drugs Register using PINs. 
Data from the day of surgery until 90 days postoperatively were included. 
3.1.1 Venous thromboembolism 
VTE was defined by a combination of ICD codes in the NPR and information on the 
prescription of anti-coagulants ≥ 30 days in the SPDR (Tables 7 and 14, appendix). By 
combining the two registers, only thromboses which received treatment were included in the 
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Figure 7. Flowchart of the patient selection in the analysis of VTE after ACLR, Study II. 
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NPR, with an ICD code indicating VTE. Some patients had a diagnosis of both DVT and PE, 
which was defined as one event of VTE. The retrieved cohort with patients who had sustained a 
VTE was compared with patients not having a VTE. The variables included in the analyses were 
based on information from the SKLR and consisted of sex, smoking, age at surgery, BMI, 
primary/revision surgery, meniscal repair, in-/out-patient surgery, operating time, choice of graft 
and the use of thromboprophylaxis. The variable of thromboprophylaxis was retrieved from the 
SKLR, as some healthcare providers hand out the drug directly to the patient and do not 
prescribe the drug (Figure 7). 
3.1.2 Septic arthritis 
The definition of SA was based on a combination of data from the NPR and SPDR. In the 
NPR, data were retrieved by using the ICD codes M00 and T84 (Table 7, appendix). In the 
SPDR, data were collected based on the prescription of antibiotics with an appropriate drug, 
dose and length of prescription for at least two weeks (Table 8, appendix). By combining data 
from these two sources, the specificity of the study was increased and only included patients who 
had been prescribed antibiotics. The selection of patients with SA was further enhanced by a 
national medical record review.  
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Figure 8. Flowchart of the patient selection in the analysis of incidence and risk factors for SA after 
ACLR, Study III. 
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The collection of medical record data included culture findings from joint aspirate and/or biopsy 
specimens, clinical signs of septic arthritis: fever ≥ 38˚C, knee effusion, CRP > 40, analysis of 
joint fluid with low glucose and increased leukocytes and documented treatment of SA. All 
patients with a positive culture were included, patients without a positive culture were included if 
clinical signs of SA were evident. Patients without medical record information were excluded. 
The time to SA was calculated from the time of surgery until the first registration in the NPR, 
with an ICD code indicating SA (Figure 8). 
The identified cohort with patients who had postoperative SA was compared with patients 
without SA. Variables retrieved from the SKLR were sex, age at surgery, BMI, smoking, in-/out-
patient surgery, primary/revision surgery, cartilage lesion, meniscal suture, choice of graft 
(hamstring tendon autograft, patellar tendon autograft, allograft and other type of graft), 
operating time and perioperative antibiotics. Patients who underwent surgery with an allograft 
and some other type of graft were excluded from the risk factor analysis, since these two 
categories consisted of small numbers. The variable of perioperative antibiotics was divided into 
four categories (cloxacillin, clindamycin, cefuroxime and other drugs), with the inclusion of the 
two most used categories in the risk factor analysis. Diabetes mellitus was defined by using data 
from the SPDR and, more specifically, information on multiple prescriptions of anti-diabetic 
drugs. Information on patients with a VTE was retrieved from Study II. Patients who were given 
a prescription for antibiotics on day 0-2 were defined as having prolonged antibiotic prophylaxis.   
3.2 ANALYSIS OF OUTCOME 
3.2.1 Analysis of non-response 
All patients who had undergone primary or revision ACLR in 2010 were included in the non-
response analysis in Study I. The cohort was divided into the two groups, respondents and non-
respondents, based on whether the patient had registered or not registered the two-year follow-
up questionnaire which consists of the KOOS and EQ-5D. The following variables were 
extracted from the SKLR: sex, age at surgery, time between injury and surgery, meniscal and/or 
cartilage lesion, choice of graft, primary or revision surgery and activity at the time of injury. 
The non-respondents were sent a reminder via mail with the same two-year follow-up 
questionnaire, together with a non-response survey. The non-response survey was created after a 
dialogue with the steering committee of the SKLR. It consisted of two pages, where the first 
page included information about the study and the second page had two “yes or no” questions 
(B1 and B2) and five statements (B3-B7) where the patient filled in the level of agreement on a 
10-point Likert scale, with 10 representing full agreement. The survey included a box for optional 
comments (Figure 12).  
The change in the KOOS and EQ-5D from preoperatively to two years postoperatively was 
analysed in the group of respondents and the group of late respondents. Patients who lacked the 







The number of patients who replied to the KOOS and EQ-5D questionnaires was not 
consistent with the number of patients who replied to the non-response survey and, as a result, 
the group in the outcome analysis differs from the group in the non-response survey (Figure 9). 
3.2.2 Subjective outcome after venous thromboembolism 
The subjective outcome for patients with a postoperative VTE was analysed with the five 
subscales of the KOOS and the two subscales of the EQ-5D. Patients with VTE were compared 
with patients with no VTE preoperatively and at one and two years postoperatively. 
3.2.3 Outcome after septic arthritis 
To study the outcome after ACLR complicated by SA in Study IV, a subgroup of the study 
population in Study III was used. Patients with a primary ACLR with a hamstring or patellar 
tendon autograft, registered in the SKLR from 2006 to 2013, were included. ACLRs performed 
with other types of graft were excluded (Figure 10).  
The patients with SA after a primary ACLR were then cross-matched with the SKLR to extract 
information on subjective outcome data (KOOS and EQ-5D index) during a five-year follow-up. 
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Figure 9. Flowchart of the patient selection in the non-response analysis, Study I. 
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Differences between the group of patients with SA and patients without SA were analysed with 
the following variables from the SKLR: sex, age at surgery, BMI, smoking, in-/out-patient 
surgery, cartilage lesion, meniscal resection, meniscal suture, operating time, choice of graft and 
perioperative antibiotics. 
The KOOS with five subscales and the EQ-5D index were analysed preoperatively and at one, 
two and five years postoperatively. Patients who underwent revision surgery during the five-year 
follow-up had their PROM data included until the event of revision surgery. 
The risk of revision ACLR within five years of the primary operation was calculated in the group 
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Figure 1. Flowchart of the patient selection. ACLR, Anterior Cruciate Ligament 
Reconstruction; SKLR, Swedish Knee Ligament Register. 
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Variables have been summarised with standard descriptive statistics such as frequency, mean, 
median, standard deviation (SD) and range depending on type and distribution of data. 
Differences between groups of categorical variables, for example, male or female, SA or no SA, 
were analysed using Pearson’s chi-square test. If an expected frequency in any cell was five or 
less, Fisher’s exact test was used. Differences between two groups with continuous variables, for 
example, mean age at surgery and operating time, were analysed with Student’s t-test. In the case 
of severely skewed variables, non-parametric tests were used, e.g. the Mann-Whitney U test for 
comparison between independent groups or Kendall’s rank correlation coefficient. The level of 
significance was five per cent (two-tailed) in all analyses. 
3.3.1 Analysis of incidence and risk factors  
3.3.1.1 Venous thromboembolism 
Based on previous knowledge the following variables were assumed to be associated with an 
increased risk of VTE: sex, age greater or equal to 40 years, thromboprophylaxis, out-patient 
surgery, revision surgery, meniscal repair and operating time greater than or equal to 90 minutes, 
and were included in a logistic regression analysis, with results presented as odds ratios (OR) with 
a 95% confidence interval (CI)(69, 70, 73). 
3.3.1.2 Septic arthritis 
The baseline analysis presented the following variables with a significant difference: sex, cartilage 
lesion, operating time, choice of graft and type of perioperative antibiotics. These five variables 
were included in a logistic regression analysis. Another two variables, BMI and VTE, were 
significant in the baseline analysis but were excluded from the analysis. BMI was excluded since 
the variable had a large number of missing values and VTE was excluded due to uncertainty of 
causality. To include the continuous variable of operating time in the regression analysis, 
dichotomisation was performed with the unbiased median value of 70.0 minutes as a cut-off. 
The results of the logistic regression analysis were presented as OR with a 95% CI. 
3.3.2 Analysis of outcome 
3.3.2.1 Analysis of non-response 
In the analysis of non-response, the baseline data for respondents vs non-respondents showed 
significant differences in sex and age at surgery. The following analyses of group differences were 
thus made with sex and age at surgery as covariates in an analysis of covariance.  
3.3.2.2 Subjective outcome after venous thromboembolism 
In the analysis of PROM, age was entered as a covariate, since there was a significant difference 
in age at surgery between the group with VTE and the group without VTE. The PROMs were 
analysed separately on each occasion; preoperatively and at one and two years postoperatively. It 
would have been preferable to use a repeated measurement design, but this would have 
introduced a great loss of power, since the PROM database in the SKLR is not complete. To 
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exemplify this, in the KOOS variable of Symptoms, only 19 of 95 patients (20%) would have 
been included, which would have affected the inclusion of all other variables. 
3.3.2.3 Outcome after septic arthritis 
The KOOS and EQ-5D index were analysed using linear mixed models with the restricted 
maximum likelihood method to estimate the change over time. Patients were included in the 
models if they had at least one input of a PROM. The within-subject variable of time was entered 
as a repeated effect with an unstructured covariance structure. Time and the between-subject 
variable group and the interaction between time*group were entered as fixed effects in the 
model. The final models also included the covariates of age at surgery, sex, choice of graft and 
cartilage injury.  
Within-subject effects were presented at each time point with 95% CI and p-value. The between-
subjects effect and mean change were presented at each time point with 95% CI and p-value. 
Proportional Cox regression was used to calculate the risk of revision ACLR within five years of 
the primary ACLR. Revision was entered as the status variable, years to revision as the time 
variable and SA as the prognostic factor in the model. The final models also included the 
covariates of age at surgery, sex, choice of graft and cartilage injury. Individuals were right 
censored if they survived up to five years, i.e. no report of an event within the study period, or if 
they died before the end of the study. The proportional hazard assumption was checked 
graphically and statistically using a log-minus-log plot entering the group variable of septic 
arthritis as stratum and by modelling the time*group interaction in a time-dependent Cox model. 
Non-parallel lines in the log-minus-log plot and a significant interaction effect in the model 
indicating a time-dependent covariate, i.e. the proportional hazard assumption, was violated.  
The hazard ratio (HR) with 95% CI is presented. 
3.3.3 Software 





3.4 ETHICAL CONSIDERATIONS 
Ethical considerations are an important part of any research. The results are presented at a group 
level and the risk of identifying a specific individual is minimal. All four studies are register based; 
it is thus relevant to consider the legislation for each register. 
3.4.1 The Swedish Knee Ligament Register 
The SKLR is regulated by the Patient Data Act and the General Data Protection Regulation 
(GDPR), previously the Personal Information Act. Once the information is extracted and used 
for research purposes, the data are regulated by the GDPR. When a patient enters the register, he 
or she is given the opportunity to opt out. 
3.4.2 Registers at the National Board of Health and Welfare 
This thesis uses three registers from the National Board of Health and Welfare (NPR, SPDR and 
CDR), all of which have absolute secrecy. The registers are regulated by the Public Access to 
Information and Secrecy Act which states, for example, when the secrecy can be voided. There is 
no consent for these registers and registration is mandatory following a political decision. 
3.4.3 Ethical permits 
To conduct research on humans, human specimens or sensitive personal information, an ethical 
permit is mandatory. These permits are processed by the Swedish Ethical Review Authority, 
which makes its decision according to the Law on Ethical Vetting and the GDPR, among others. 
This thesis has three permits from the regional ethics committee in Stockholm (which was 
replaced by the Swedish Ethical Review Authority on 1 January, 2019): 2011/337-31/3, 
2013/1257-31/3 and 2017/408-32.  
 
Applicable laws – Swedish translations 
The General Data Protection Regulation (GDPR), EU 2016/679 – Dataskyddsförordningen  
The Patient Data Act – Patientdatalag (PDL)(2008:355) 
The Personal Information Act – Personuppgiftslag (PUL)(1998:204) 
The Public Access to Information and Secrecy Act – Offentlighets- och sekretesslag (OSL)(2009:400) 





4.1 INCIDENCE AND RISK FACTORS 
The study population consisted of 25,197 patients. Eight hundred and seventeen patients had 
two or more operations and the total number of ACLRs was 26,014, of which 1,619 (6.2%) were 
revision procedures. Three patients died of unrelated causes such as a gunshot wound, fall from 
height and alcohol-related death. One patient, a 21-year-old man, died of an unknown cause, 58 
days following surgery. 
4.1.1 Venous thromboembolism 
The total number of VTEs was 95 (0.4%) with a mean time from surgery to VTE of 15.1 days 
(range 1 to 86)(Figure 7). Differences between the group with VTEs as compared with the group 
without VTEs are presented in Table 9, appendix. The only independent risk factor for VTE 
following the logistic regression analysis was age at surgery greater than or equal to 40 years 
(odds ratio 2.31, 95% CI 1.45-3.70)(Table 1). Thromboprophylaxis was prescribed at 36.4% of 
the performed surgeries, with no difference between the group with VTE and the group without 
VTE. 
 
 Table 1. Risk factors for venous thromboembolism in a logistic regression analysis 
 Reference category Beta coefficient 
Odds 
ratio 95% CI p-value 
Patient demographics      
 Male sex Female sex 0.26 1.30 0.85-1.98 0.232 
 Age ≥40 yrs < 40 yrs 0.84 2.31 1.45-3.70 <0.001 
 Thromboprophylaxis No thromboprophylaxis 0.11 1.11 0.72-1.71 0.628 
      
Perioperative data      
 Out-patient surgery In-patient surgery 0.60 1.83 0.99-3.37 0.053 
 Revision surgery Primary surgery 0.03 1.03 0.42-2.56 0.946 
 Meniscal repair No meniscal repair 0.60 1.83 0.91-3.69 0.092 
 Operating time ≥90 min < 90 min -0.49 0.62 0.36-1.04 0.072 
      
Constant n/a -6.99 n/a n/a n/a 
CI, confidence interval, n/a, not applicable 
 
4.1.2 Septic arthritis 
The total number of SA identified in the cohort of 26,014 ACLRs was 298, corresponding to an 
incidence of 1.1% (Figure 8). The 16 high-volume units, with ≥ 500 ACLRs during the study 
period, had a distribution of SA from 2 to 47 (0.2-2.9%) and there was no significant difference 
compared with the distribution in the low-volume units (1.1 vs 1.2%, p=0.273). The mean time 
from surgery to diagnosis of SA was 18.4 days (range 1 to 74). Differences between the group 
with SA and the group without SA are presented in Table 13a and 13b, appendix. 
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The logistic regression analysis of the risk factors established male sex, operating time ≥ 70 
minutes, a hamstring tendon autograft and clindamycin as independent risk factors for SA (Table 
2). 
Table 2. Risk factors for septic arthritis in a logistic regression analysis 
 Reference category Beta coefficient 
Odds 
ratio 95% CI p-value 
Patient demographics      
 Male sex Female sex 0.50 1.65 1.28-2.13 <0.001 
      
Perioperative data      
 Cartilage lesion No cartilage lesion 0.24 1.27 0.99-1.63 0.062 
 Operating time ≥ 70 min < 70 min 0.61 1.83 1.42-2.36 <0.001 
 Hamstring tendon autograft Patellar tendon autograft 0.80 2.23 1.21-4.08 0.010 
 Clindamycin Cloxacillin 0.66 1.94 1.10-3.41 0.022 
      
Constant n/a -7.14 n/a n/a n/a 
CI, confidence interval; n/a, not applicable 
 
4.2 OUTCOME 
4.2.1 Analysis of non-response 
4.2.1.1 Validation of key baseline data 
The study of non-response included 3,588 patients, of which 41.1% were females. At the two-
year follow-up, 1,865 were respondents and 1,723 were non-respondents. The respondents had a 
significantly higher age at surgery and contained a greater proportion of females than the non-
respondents (Table 3). 





Sex    
 Female, n=1,476 927 (62.8%) 549 (37.2%) <0.001 
 Male, n=2,112 938 (44.4%) 1,174 (55.6%)  
Age, years (range) 27.8 (9-64) 25.9 (12-65) <0.001 
Time to surgery, days (SD) 244 (4.44) 256 (4.84) 0.074 
SD, standard deviation 
 
4.2.1.2 Analysis of KOOS and EQ-5D 
The KOOS and EQ-5D for respondents and late respondents, preoperatively and at two years 
postoperatively, are presented in Table 10 and 11, appendix. The improvement in the KOOS 
from preoperatively to two years postoperatively is displayed in Figure 11, where the subscales of 
Pain and Knee-Related Quality of Life show significantly lower scores for the late respondents as 
compared to the respondents. The analysis of the EQ-5D revealed no significant differences 

















4.2.1.3 Non-response survey 
The non-response survey had a response rate of 20.3%, with 40.3% women. The first question, 
B1 “Did you, at the time of surgery, receive information about the SKLR”, only had a 60% level 
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Figure 11. The improvement in the KOOS from preoperatively to the two-year follow-up presented 
in each subscale for respondents and late respondents. Data adjusted for age at surgery and sex.  




4.2.2 Subjective outcome after venous thromboembolism 
The group with VTE had a significantly poorer outcome on all subscales of the KOOS and EQ-
5D compared with the group without VTE at one year postoperatively. At two years 
postoperatively, the difference remained but was only statistically significant in the KOOS 
subscales of Activity of daily living (85.9 vs 90.8, p=0.030) and Sport and recreational function 
(55.3 vs 64.3, p=0.046)(Table 12, appendix). 
4.2.3 Outcome after septic arthritis 
The outcome after SA was analysed in a subgroup from the incidence analysis and included 
23,075 primary ACLRs, with 268 (1.2%) events of SA. The within-subject and the between-
subject effects are presented in Table 4. The fixed effects of time*SA were significant in the 
KOOS subscales of Symptoms, Pain, Sport and recreational function and Knee-related quality of 
life (Figure 14). 
The overall rate of revision ACLR was 4.3%. Patients with SA ran an increased risk of revision 
ACLR, with an adjusted HR of 2.04 (95% CI 1.34 to 3.12)(Figure 13). The median time to 
revision surgery was 800 (range from 254 to 1,825) days for patients with SA and 1,020 (range 
from 42-1,825) days for patients without SA. 
 
 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 14. Mean values of the KOOS subscales and the EQ-5D index for the groups with and without 
septic arthritis, preoperatively (0 years) and at each follow-up occasion (1, 2 and 5 years postoperatively). 
Adjusted for the covariates age at surgery, sex, cartilage lesion and choice of graft.  
Whiskers displaying 95 % confidence interval. 
SA, septic arthritis; ADL, activity of daily living; sport/rec, sport and recreational function; QoL, knee-related 




By combining different types of registers, this thesis presents two rare complications following 
ACLR. The incidence, the risk factors and the outcome of VTE and SA are investigated and 
established. 
5.1 INCIDENCE AND RISK FACTORS FOR VENOUS THROMBOEMBOLISM 
The finding of an incidence of VTE after ACLR of 0.4% is low and in agreement with previous 
published literature (69, 70, 111). The corresponding incidence in a general population in the age 
group of 25-35 years is 0.03%, while it is 0.07% in a middle-aged female population (65, 112). 
However, when calculating the risk of VTE during a three-month period for these two study 
populations, the risk decreases to 0.008% and 0.018% respectively. Based on these findings, the 
risk of a VTE within three months of an ACL reconstruction is 20 to 50 times higher as 
compared with a population not having surgery. 
 
 
Table 5 illustrates previous findings of incidence and risk factors for VTE compared with the 
results of this thesis. The study populations are somewhat smaller, but the findings are similar, 
with the exception of the study by Gaskill et al., who report risk factors from a univariate 
analysis. A higher incidence, between 7% to 14%, is reported when patients are screened 
postoperatively for VTE; with approximately half being asymptomatic (71, 72, 74). One 
explanation of the diverging incidence of VTE between studies with postoperative screening and 
no screening is that the symptoms of VTE are similar to the normal symptoms in the early 
postoperative period, where the leg is swollen and painful, and difficult to differentiate from each 
other.  
The risk factor of older age is reported in the majority of studies listed in Table 5. Age is a known 
risk factor for VTE in a general population (65). Specific risk factors in the ACLR setting have 
not been identified by the register-based studies in Table 5. Operating time of more than 90 
minutes has been associated with an increased risk of PE in a study by Hetsroni et al., of 418,323 
knee arthroscopic procedures, which also demonstrated that ACLR has a lower, albeit not 
significant, risk of PE as compared with having a meniscectomy (73). The increased risk of PE 
with a longer operating time could be attributed to the use of a tourniquet, a variable not 
included in the study by Hetsroni et al., whereas Dong et al. reported a relative risk of DVT in 
Table 5. Reports on the incidence of and risk factors for VTE after ACLR 






risk factors Odds ratio, (CI) 
Jameson et al. (69) 2012 13,491 0.4% Age > 40 years* 2.36 (1.29-4.34)* 
Maletis et al. (111) 2013 16,192 0.3% Not reported - 
Gaskill et al. (70) 2015 16,558 0.5% Age ≥ 35 years† 1.96 (1.27-3.04)† 
    Use of NSAID 0.44 (0.28-0.70) 
    Use of anticoagulants 98.32 (61.63-156.86) 
Kraus Schmitz et al. 2019 26,014 0.4% Age ≥ 40 years* 2.31 (1.45-3.70)* 
CI, confidence interval, *multivariate analysis, †univariate analysis 
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patients having a tourniquet for > 120 minutes of 3.6 as compared with patients having a 
tourniquet for < 90 minutes (74). However, the data from Dong et al. included multi-ligament 
procedures and the risk factor analysis was univariate. The risk of tourniquet use during surgery 
has not been fully investigated. Hirota et al. analysed the amount of emboli formation in the right 
atrium with transoesophageal echocardiography following the deflation of a tourniquet. They 
compared patients who underwent ACLR and total knee arthroplasty (TKA) and found that 
both groups had a substantial increase in emboli at the time of deflation with significantly more 
emboli in the group that underwent TKA. They also found that the number of emboli correlated 
positively to tourniquet time in both groups. Despite the formation of emboli, no PE was 
detected among the 40 patients (113). In a meta-analysis of patients who underwent TKA with 
and without the use of a tourniquet, no difference in the occurrence of DVT or PE was 
demonstrated (114). The SKLR does not include information on the use of a tourniquet, but 
Ekdahl et al. reported that more than half the Swedish ACL surgeons always use a tourniquet 
(76). 
Female sex was shown to be an independent risk factor for PE in the study by Hetsroni et al. 
(73). In a general population, no such relationship has been proven (65). The finding by Hetsroni 
et al. could be explained by the use of oral contraceptives, a known risk factor for VTE (115). 
The data presented in this thesis did not reveal any difference between female and male patients 
and no data on oral contraceptives were included. 
Thromboprophylaxis was prescribed to approximately one third of the patients in the study of 
VTE, with no difference between the group with VTE and the group without VTE. There are 
no specific recommendations for thromboprophylaxis in the ACLR setting and the American 
College of Chest Physicians only recommends thromboprophylaxis if the patient has a history of 
thrombosis (75). A Dutch study by van Adrichem of 1,451 patients undergoing knee arthroscopy 
was unable to prove any benefit of thromboprophylaxis (116). In the study by Gaskill et al., 147 
(0.9%) patients received thromboprophylaxis and had an increased risk of VTE. This paradoxical 
finding is explained by a probable selection bias, i.e. the patients receiving thromboprophylaxis 
were probably identified as having a high risk of thrombosis. Based on the findings in this thesis, 
it was therefore inappropriate to draw any conclusions regarding thromboprophylaxis. 
5.2 INCIDENCE AND RISK FACTORS FOR SEPTIC ARTHRITIS 
The incidence of septic arthritis after ACLR was 1.1%. All types of surgery include a risk of 
postoperative infection, which has a probable effect on the outcome. In orthopaedic surgery, 
arthroplasty of the knee and hip are common procedures, and the incidence of periprosthetic 
joint infection after hip arthroplasty is reported to be around 1% and from 1% to 2% for knee 
arthroplasty (117).  
The incidence of SA in this thesis is compared with previous findings from register-based studies 
in Table 6. The methods for establishing a postoperative SA differ between the studies. 
However, none of the studies has used the method applied in this thesis, where several different 
sources of information (diagnosis codes, prescription of antibiotics and medical records) are 
combined in order to establish an incidence with a high specificity and a sensitivity. The low loss 
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to follow-up could be one explanation of the higher incidence as compared to the studies by 
Brophy and Westermann. This is further illustrated by findings from studies at single institutions, 
which have a low loss to follow-up and report a higher incidence of SA, from 0.6 to 1.8% (87, 
88, 94, 118). 
 
Another explanation for the somewhat diverging incidence of SA is the choice of graft, which 
has been proposed to have an impact on the incidence of SA. In this thesis, the majority of the 
ACLRs, 91%, were performed with hamstring tendon autografts. Previously, the hamstring 
tendon autograft as compared to the patellar tendon autograft has been reported as a risk factor 
for SA after ACLR (90, 119, 120), a finding confirmed by this thesis, where hamstring tendon 
autograft is an independent risk factor for postoperative SA after ACLR as compared to the use 
of a patellar tendon autograft, with more than double the odds of sustaining a postoperative SA. 
It is postulated that the hamstring tendon is more easily contaminated during harvest and 
preparation, before insertion into the knee joint (90, 119, 120). This is further supported by a 
study on soaking the graft in vancomycin, where seven of 50 grafts were contaminated during 
harvest or preparation but had negative cultures following soaking the graft with vancomycin 
(121). Another aspect and possible cause of the increased risk of infection is that the hamstring 
tendon is normally folded twice (quadrupled) and has a larger surface exposed to bacteria as 
compared to patellar tendon autografts and quadriceps tendon autografts, which are prepared 
“en bloc”. During the study period of this thesis, vancomycin was not used to soak the graft 
during preparation. In a survey of Swedish ACL surgeons in 2017, 8% reported the use of 
vancomycin to soak the graft (76).  
Perioperative antibiotic prophylaxis was used in all ACLRs and the use of clindamycin instead of 
cloxacillin increased the risk of SA with an, almost, doubled odds ratio. This is a novel finding in 
the ACLR setting. In a report from the Swedish Knee Arthroplasty Register, the risk of revision 
surgery due to infection was doubled when clindamycin was used instead of cloxacillin as the 
perioperative antibiotic (122). In Sweden, the use of clindamycin is reserved for patients 
reporting an allergy to penicillin. However, Robertson et al. emphasised that, with a more 
detailed history of the patient’s report of allergy, a possible type I allergy can be ruled out and a 
second- or third-generation cephalosporin can safely be used. The reason for the inferior effect 
of clindamycin has not been established. Robertson et al. point out two possible reasons; its 
Table 6. Reports on the incidence of and risk factors for SA after ACLR 






risk factors Odds ratio, (CI) 
Westermann et al. (85) 2017 6,398 0.3% Hospital admission 2.67 (1.65-3.69)* 
Brophy et al. (90) 2015 2,198 0.8% Diabetes mellitus 18.8 (3.76-93.97)* 
    Graft choice (HT vs PT) 4.63 (1.20-17.91) 
Cancienne et al. (86) 2016 13,358 1.0% Tobacco use 2.3 (1.6-3.4)† 
Kraus Schmitz et al. 2021 26,014 1.1% Male sex 1.65 (1.28-2.13)* 
    Operating time ≥ 70 min 1.83 (1.42-2.36) 
    Graft choice (HT vs PT) 2.23 (1.21-4.08) 
    Choice of antibiotics (CL vs CX) 1.94 (1.10-3.41) 
CI, confidence interval; HT, hamstring tendon autograft; PT, patellar tendon autograft; CL, clindamycin; CX, cloxacillin; *multivariate 
analysis, †univariate analysis 
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bacteriostatic mechanism compared with beta-lactams, which have a bacteriolytic effect, and the 
dilution of the drug due to a high intracellular distribution (122). 
Prolonged antibiotic prophylaxis, i.e. when the patient is prescribed oral antibiotics for a number 
of consecutive days following surgery, was used in 6.5% of all ACLRs, with no statistical 
difference between the group with SA and the group without SA. There is no scientific support 
for using prolonged prophylaxis and it is thought that its use could increase antibiotic resistance 
(98, 99).  
This thesis showed that an operating time of more than or equal to 70 minutes as compared to 
less than 70 minutes increased the risk of infection with an OR of 1.83. The relationship between 
longer operating times and the risk of infection has previously been established in surgical 
procedures in general (123), as well as in the ACLR setting (124). The mechanism by which the 
risk of infection is increased is not fully established. In open surgery, the wound has a longer 
exposure to the environment and potential bacterial contamination (123), but this is not fully 
applicable in ACLR, where most of the surgery is performed through two or three portals with 
openings of less than two centimetres and a small, approximately 3-5 cm incision for graft 
harvesting. However, the instruments are taken in and out of the portals, which is a probable 
source of contamination, as well as the graft contamination mentioned previously. With longer 
operating times, there is a risk of fatigue in the surgical team, which could increase the risk of 
surgical errors (123). 
Male sex was another independent risk factor for SA after ACLR, with an OR of 1.65, which is 
lower than the other presented risk factors. This is a novel finding in ACL surgery, but it has 
been demonstrated in total knee arthroplasty surgery (125, 126). In SA following invasive 
pneumococcal disease, male sex has been shown to be an independent risk factor (127). With the 
data presented in this thesis, the risk factor of male sex cannot be explained. 
5.3 OUTCOME 
Knowledge regarding the outcome of the two rare complications, VTE and SA, facilitates the 
decision on how and when preventive measures should be used. The possible lethal outcome of 
VTE is discussed earlier in the background section. This thesis clarifies the subjective knee 
function of patients who experienced the complications of VTE and SA, as well as the risk of 
revision ACLR after SA. 
5.3.1 Non-response analysis 
With increasing follow-up times, the response rates to the KOOS and EQ-5D questionnaires 
decreases in the SKLR. The non-response analysis demonstrated small differences of KOOS 
between the response and non-response groups with questionable clinical outcome.  
Women and older patients responded to a greater degree than men and younger patients, which 
is in agreement with previous study findings (128-130). This is important knowledge, since it has 
previously been shown that sex and age influence the KOOS. Female patients respond with a 
poorer KOOS as compared to male patients in several studies (102, 131, 132) and no difference 
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in objective knee function between the sexes has been established (131, 132). The patient’s age 
appears to influence the reported subjective outcome, but the results from previous studies 
diverge. Desai et al. report that patients aged 40 years and older have a lower preoperative 
KOOS and a greater improvement in the KOOS compared with younger patients (101), which 
could suggest that the older patients that undergo surgery have a poorer function and have more 
to gain from surgery. In contrast, several authors report a higher postoperative KOOS in 
younger patients (100, 133). 
The non-response analysis of the KOOS showed that, after adjustment for age and sex, there 
was a significantly greater improvement, from preoperatively to the two-year follow-up in the 
subscales of Pain and Knee-related Quality of Life, for the respondents compared with the late 
respondents. Whether or not these differences are clinically applicable remains to be answered, 
but this should at least be considered when analysing the subjective outcome data. 
The reasons for not responding were investigated with a separate questionnaire which had a 
response rate of 20%. Among the respondents to the questionnaire, 40% answered that they had 
not been given information about the SKLR preoperatively, which indicates that there is room 
for improvement regarding information about the SKLR given to the patient. 
5.3.2 Subjective outcome after venous thromboembolism 
The KOOS and EQ-5D were analysed at the one- and two-year follow-ups for patients with 
VTE and compared with patients without VTE. The former group had poorer outcomes on all 
follow-up occasions at one year and in the KOOS subscales of Activity of daily life and Sport 
and recreational function at two years. This is a novel finding with subjective outcome data for 
patients with a VTE following ACLR and one possible explanation of the initially poorer 
outcome could be a delay in rehabilitation due to the VTE. 
5.3.3 Outcome after septic arthritis 
The outcome for patients with SA after primary ACLR was analysed with the KOOS and EQ-
5D index preoperatively and at one, two and five years postoperatively and with the five-year risk 
of revision ACLR. 
On all the postoperative follow-up occasions, patients with SA presented with a significantly 
poorer outcome compared with patients without SA. The patients without SA experience a 
gradual improvement in the KOOS on each follow-up occasion. The opposite is seen among 
patients with SA in the KOOS subscales of Symptoms, Pain, Sport and recreational function and 
Knee-related quality of life, where the scores are without change or even worse at the two- and 
five-year follow-ups compared with the one-year follow-up. The same subscales demonstrate a 
significant improvement with time for the group without SA compared with the group with SA. 
Overall, this analysis demonstrates that patients with SA after primary ACLR have a poorer long-
term subjective outcome. 
The subjective outcome after ACLR complicated by SA is reported in several studies but with a 
small number of patients with SA and with different types of outcome scores. Makhni et al. 
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presented a review with data on the Lysholm score, with no difference between 160 infected 
patients and patients without infection, and data on the IKDC score, where the infected patients 
obtained lower scores than patients without infection (110). However, the data presented in the 
review only included the infected patients and data on the control groups were taken from other 
studies of uninfected patients.  
Boström Windhamre et al. presented data from a Swedish clinic on 27 patients with a 
postoperative SA. During a follow-up of 60 months, no difference in the improvement of the 
KOOS could be noted between patients with and without SA (94). Similar findings, with no 
difference between the groups, were presented by Abdel-Aziz et al. for 24 patients with a 
postoperative SA during a follow-up period of 59 months (134). 
The explanation for the lower PROMs among patients with SA has not yet been established. The 
pathogenesis in septic arthritis is complex and depends on numerous factors such as the host 
immune response and the pathogen. The joint damage can be divided into three mechanisms; 
the bacterial toxins and enzymes, which have a direct injurious effect on the cartilage, the host 
inflammation response, with the release of collagen-degrading enzymes, and asphyxia in the joint, 
due to an increase in intra-cellular pressure (78, 81). In a Norwegian study, Rötterud et al. 
demonstrated that patients with a focal full-thickness cartilage lesion at the time of ACLR had a 
poorer outcome and a poorer improvement in the KOOS compared with patients without 
cartilage lesions (135). Based on these findings, it is possible that the lower PROM among the 
patients with SA is explained by the cartilage deterioration caused by the infection and a more 
rapid development of osteoarthritis (136, 137). Other explanations include the risk of developing 
arthrofibrosis following an infection, which affects the outcome negatively (138). 
Revision ACLR within five years of primary ACLR was almost twice as high in the group with 
SA (8.2%) compared with the group without SA (4.2%), which is a novel finding in the ACLR 
setting. Following an adjustment for previously identified risk factors for revision surgery, age at 
surgery, sex, graft choice and cartilage lesions, the hazard ratio for patients with SA indicated 
more than twice the risk of revision ACLR. This finding, together with the finding of a poorer 
subjective outcome, could indicate that the graft is of poorer quality and runs an increased risk of 




6 STRENGTHS AND LIMITATIONS 
The main strengths of this thesis are the presentation of novel findings from the risk factor 
analyses and the finding of poorer outcome for patients with a postoperative SA after ACLR.  
These findings are important to recognise in order to improve the care of patients who undergo 
ACLR, both to decrease the risk of complications but also to better support the patients which, 
after all is affected. Using a nationwide population of considerable size and methods for 
combining registers and review of medical records, it is probable that the incidence and risk 
factor analyses have yielded high sensitivity and specificity. 
However, the use of registers has limitations. To establish the true incidence of the complications 
and the impact on outcome, a follow-up of 100% is needed and, to evaluate the risk factors 
accurately, a cohort that is of considerable size is desirable. The combination of these two 
aspects is difficult to achieve. An analysis of registers is normally associated with a loss to follow-
up, whereas the number of included patients can be extensive. The opposite is normally applied 
to a prospective study at a single institution, where a follow-up of 100% is achievable, but the 
study population is normally smaller. 
As mentioned in the literature review section, two important factors in a register are coverage 
and completeness. The SKLR is estimated to have completeness of more than 90%, which could 
introduce a selection bias, as we have no information on the patients who underwent surgery and 
were not registered in the SKLR (21). 
The registers at the Swedish National Board of Health and Welfare are modelled to have 
coverage of 100%. The completeness is dependent on various circumstances, e.g. the NPR is 
dependent on the coding made by the treating doctor, whereas the registration in the SPDR is 
automated with the transfer of data from the Swedish eHealth Agency to the Swedish National 
Board of Health and Welfare on a monthly basis (54-56). Another aspect is the correctness of 
the register and the in-patient register (a part of the NPR) has an overall positive predictive value 
(PPV) of 85-95% (53). 
6.1 SPECIFIC LIMITATIONS REGARDING THE ANALYSIS OF INCIDENCE  
6.1.1 Venous thromboembolism 
Different degrees of uncertainty are attributed to the diagnosis codes for DVT and PE. Öhman 
et al. presented data from the NPR and CDR from 1985 to 2014 and found a PPV of 81% for 
PE and 59% for DVT. They concluded that the data on DVT should not be used without 
validation (139). Alotabi used a Canadian database to demonstrate PPVs of 71% and 77% for PE 
and DVT respectively (140). The sensitivity of using diagnosis codes for VTE was 75% (140). In 
this thesis the SPDR was used to confirm and validate the findings of VTE, a method previously 
used in the US and on Danish register data (141, 142). Using this method, the PPV increases 
close to 100%, as false positive cases, i.e. patients who are misdiagnosed as VTE, are excluded. 
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6.1.2 Septic arthritis 
In the analysis of septic arthritis, the same process as with VTE was used, with a combination of 
data from the NPR and SPDR. However, to further increase the accuracy of the diagnosis, a 
third process was included; it consisted of a medical record review of all patients with suspected 
SA following the register analyses. This third process excluded potential remaining false positive 
cases which consisted of 17 patients (5%). To summarise, if the analysis were to be repeated 
without the medical record review, an error rate of 5% for detection of SA would be introduced. 
6.2 SPECIFIC LIMITATIONS REGARDING THE ANALYSIS OF RISK FACTORS 
The risk factor analysis is based mainly on the demographic and perioperative variables included 
in the SKLR, which are based on the patient’s and the surgeon’s input. As it is not mandatory to 
register all variables, a possible selection bias is introduced. Some of the variables, such as BMI, 
have a large number of missing values and have been addressed specifically in the discussion. 
6.2.1 Venous thromboembolism 
In the analysis of risk factors for VTE, there is no information regarding previous thrombosis or 
ongoing oral contraceptive therapy, both known risk factors for VTE. It is thus possible that 
some patients have an increased risk of VTE, which introduces a bias in the interpretation of the 
risk factors. However, sex was included in the logistic regression model and no effect on the risk 
for VTE was demonstrated. 
6.2.2 Septic arthritis 
The analysis of SA lacks information on specific institutional data, including the preoperative 
preparation of the patient, equipment and ventilation in the operating room and perioperative 
routines, factors that could have an effect on the risk of postoperative SA. 
The risk factor analysis included variables from the SKLR, as well as variables retrieved from the 
NPR and SPDR. Information on VTE was retrieved from Study II, but, due to uncertainty 
regarding causality, the variable was not included in the logistic regression analysis. The variable 
of diabetes mellitus was based on a proxy: multiple prescriptions of anti-diabetic drugs in the 
SPDR, a method previously shown to be highly reliable by Rawshani et al. (143). 
6.3 SPECIFIC LIMITATIONS REGARDING THE ANALYSIS OF OUTCOME 
The analysis of PROMs is limited by the decreasing rate of completed questionnaires for each 
follow-up occasion, which is taken into consideration by including a non-response analysis. 
6.3.1 Non-response analysis 
The major limitation in the non-response analysis is that only 17% of the non-respondents were 
included in the analysis of the KOOS and EQ-5D. This raises concerns about the validity of the 
results and they can only be assumed to be valid for the whole non-response group. 
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6.3.2 Subjective outcome after venous thromboembolism 
The data on the KOOS and EQ-5D for patients with and without VTE differ substantially in 
size (55 vs 13,385 for KOOS Pain at one year postoperatively) and the same applies to the 
confidence intervals. It is possible that only small changes in the PROMs in the group with VTE 
could alter the findings, which should be taken into account when interpreting the data. 
6.3.3 Outcome after septic arthritis 
The analyses of outcome after SA have no information on perioperative data at the time of 
infection. The number of I&Ds performed, together with the properties of the graft, would be 
valuable information to enable an even better estimate of the impact of the infection. At follow-
up, information on return to sport, objective knee function and the possible development of 
osteoarthritis on X-rays would be valuable information to enable a better understanding and 
evaluation of the outcome after SA. The analysis of the KOOS and EQ-5D index has 
shortcomings similar to those in the analysis of subjective outcome after VTE. On the other 
hand, the group with SA is larger, but the disparity in group size between the group with SA and 






The general conclusions of this thesis are as follows. 
• Using register-based data, analyses of rare complications are possible to achieve. 
• The studied complications are rare and in line with previous findings. The incidence of 
VTE and SA after ACLR are 0.4% and 1.1% respectively. 
• The risk factor analysis demonstrated that older age at surgery is the only independent 
risk factor for VTE after ACLR, whereas male sex, longer operating times, the use of 
clindamycin instead of cloxacillin and hamstring tendon autografts instead of patellar 
tendon autografts are all independent risk factors for SA after ACLR. 
• Females and older patients have a higher response rate in the SKLR. There are small 
differences in the KOOS between respondents and non-respondents. The information 
about the SKLR given to the patient could be improved. 
• Patients with VTE after ACLR have a poorer subjective outcome than patients without 
VTE, which also applies to patients with SA. The analysis of improvement in the KOOS 
indicates a poorer long-term outcome for patients with SA after ACLR. 
• Patients with SA after ACLR run double the risk of revision ACLR as compared to 
patients without SA. 
• The method used in the analysis of incidence of SA confirmed that, wihout using a 




8 POINTS OF PERSPECTIVE 
Two rare complications following ACLR are outlined in this thesis and the question of whether 
they are avoidable remains. The short answer is no, but the risk factor analyses have shown that 
some parts of patient care are possible to modify, with a probable decrease in the risk of 
complications. 
8.1 VENOUS THROMBOEMBOLISM 
The only independent risk factor for VTE was age of 40 years and older, which is a non-
modifiable risk factor. What is not answered by the present study is whether thromboprophylaxis 
should be used. With the already low incidence of VTE and a probable small risk reduction with 
thromboprophylaxis, a fairly large study population is needed to verify whether or not 
thromboprophylaxis should be used. The number needed to treat is likely to be high and the 
side-effects, such as bleeding, must be taken into account. Nevertheless, for the affected patient, 
the consequences of a VTE can be devastating and it is extremely important to have a well-
informed patient before surgery. 
Future perspectives on the study of VTE after ACLR could include analyses of oral contra-
ceptives and whether this poses an increased and perhaps modifiable risk of VTE. 
8.2 SEPTIC ARTHRITIS 
Male sex was an independent risk factor for SA. In the light of the corona pandemic, where male 
sex is a risk factor for hospital admission and mortality (144, 145), together with previously 
mentioned studies where male sex is a risk factor for infection following total knee arthroplasty, 
the question of whether it is the sex per se or whether it is a proxy for an unknown factor 
remains to be answered. 
The modifiable risk factors of operating time, choice of graft and perioperative antibiotics are 
easier to address. Normally, the surgeon strives to perform the surgery as thoroughly as possible, 
without unnecessary delays. Increasing the number of surgeries per surgeon, improvements in 
local routines and fully functional equipment are possible factors that could reduce the operating 
time. 
Graft choice is made with several factors in mind and every type of graft has different advantages 
and disadvantages. Soaking the graft in vancomycin is a novel method for reducing the incidence 
of postoperative SA. To date, the published studies have shown promising results with no 
postoperative infections (146). However, the studies are all retrospective in design, which raises 
concerns regarding their validity – other unregistered factors that reduce the incidence of SA may 
have been introduced, together with the introduction of vancomycin. Lastly, the results in this 




The choice of perioperative antibiotics is influenced by the presence of allergy to penicillin. As 
discussed, a more detailed allergy history can reveal the type of allergy and a drug other than 
clindamycin can safely be used instead. 
8.3 OUTCOME 
The subjective outcome is affected and reduced by the studied complications. All the analyses 
of subjective outcome are biased by their low response rates, which the non-response analysis 
attempted to shed some light upon. It is essential to evaluate the outcome for any administered 
treatment. Following ACLR, response rates could be improved by better information of the 
SKLR, and perhaps with user-friendly mobile applications and some kind of feedback of the 
rehabilitation related to the responses of PROMs. 
The risk of revision ACLR is increased among patients who have a postoperative SA. This 
raises a final interesting question; is revision ACLR in general, associated with infection to a 
greater extent than shown in this thesis? Recent reports have found bacterial DNA at the time 
of revision ACLR (147), which could indicate a subclinical infection. This is a finding that 
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  Table 7. ICD-codes 
ICD 10-code Diagnosis 
I26.0 Pulmonary embolism with mention of acute cor pulmonale 
I26.9 Pulmonary embolism without mention of acute cor pulmonale 
I80.0 Phlebitis and thrombophlebitis of superficial vessels of lower extremities 
I80.1 Phlebitis and thrombophlebitis of femoral vein 
I80.2 Phlebitis and thrombophlebitis of other deep vessels of lower extremities 
I80.3 Phlebitis and thrombophlebitis of lower extremities, unspecified 
I80.8 Phlebitis and thrombophlebitis of other sites 
I80.9 Phlebitis and thrombophlebitis of unspecified site 
I82.8 Embolism and thrombosis of other specified veins 
I82.9 Embolism and thrombosis of unspecified vein 
M00 Pyogenic arthritis 
T84 Complication of internal orthopaedic devices, implants and graft 
ICD, International Classification of Disease 
 
Table 8. ATC code, type of antibiotic and dosage used in the selection process. 
ATC code Antibiotic Daily dose 
J01CA04 Amoxicillin 750 mg 1x3 
J01CR02 Amoxicillin and clavulanic acid 500/125 mg 1x3 
  875/125 mg 1x2 
J01DB05 Cefadroxil 500 mg 1x2 
  1 g 1x2 
J01MA02 Ciprofloxacin 250 mg 2x2 
  500 mg 1x2 
  750 mg 1x2 
J01CE02  Phenoxymethylpenicillin 1 g 2x3 
J01CF05 Flucloxacillin 500 mg 2x3 
  750 mg 2x3 
  1g 1x3 
J01XC01 Fusidic acid 250 mg 2x3 
J01FF01 Clindamycin 150 mg 1x3 
  300 mg 1x3 
J01MA12 Levofloxacin 500 mg 1x1 
J01XX08 Linezolid 600 mg 1x2 
P01AB01 Metronidazole 400 mg 1x3 
J01MA14 Moxifloxacin 400 mg 1x1 
J04AB02 Rifampicin 600 mg 1x1 
J01EE01 Sulfamethoxazole and trimethoprim 80/400 mg 2x2 
  160/800 mg 1x2 







































































































































































































































































































































































Table 11. EQ5D index and EQ5D VAS presented preoperative and at two-years 
for respondents and late respondents with mean and 95% confidence intervall. 
  EQ5D subscales 
Index VAS 
Respondents Pre op. 0.68 (0.67-0.70) 61.4 (60.1-62.8) 
 Two yrs 0.81 (0.80-0.82) 75.9 (74.8-76.9) 
Late Respondents Pre op. 0.66 (0.63-0.69) 62.1 (58.9-64.8) 
 Two yrs 0.79 (0.77-0.82) 75.4 (72.8-77.7) 
VAS, visual analogue scale 
 
Table 10. KOOS for each subscale presented preoperatively and at two-years postoperatively for respondents and 
late respondents with mean and 95% confidence intervall. 
  KOOS subscales 
 Symptoms Pain ADL Sport/Rec QoL 
Respondents Pre op. 70.5(69.6-71.6) 75.1(74.2-76.1) 83.3(82.4-84.3) 40.6(39.3-42.2) 33.8(32.9-34.9) 
 Two yrs 77.8(76.8-78.8) 84.5(83.6-85.4) 91.1(90.4-91.9) 65.3(63.8-66.8) 59.9(58.5-61.1) 
Late Respondents Pre op. 70.6(68.4-72.8) 74.9(72.5-76.7) 84.1(81.8-85.9) 43.5(39.9-46.2) 33.2(30.7-35.2) 
 Two yrs 74.8(72.7-77.0) 81.2(79.2-83.1) 89.1(87.4-90.6) 62.5(59.1-65.5) 55.8(53.2-58.9) 
ADL, activity of daily life; Sport/rec, sport and recreational function; Qol, knee-related quality of life 
 
Table 12. Mean scores of the KOOS and EQ5D subscales for patients with and without venous thromboembolism. 
Scores are presented preoperatively and at one and two years postoperatively. Data is adjusted for age. 
     VTE  Non-VTE P Value 
   n Mean score (95% CI) 
 n Mean score (95% CI) 
KOOS Symptoms pre-op 68 67.5 (63.1-71.9)  17,542 70.0 (69.7-70.3) 0.267 
 one yr 55 64.2 (59.3-69.0)  13,385 76.4 (76.1-76.8) < 0.001 
  two yrs 39 72.2 (66.5-78.0)  11,799 77.6 (77.2-77.9) 0.069 
KOOS Pain pre-op 68 72.9 (68.7-77.1)  17,543 74.6 (74.4-74.9) 0.419 
 one yr 55 74.8 (70.4-79.1)  13,385 83.6 (83.4-83.9) < 0.001 
  two yrs 39 79.1 (73.9-84,3)  11,801 84.0 (83.7-84.3) 0.062 
KOOS ADL pre-op 68 82.3 (78.3-86.3)  17,541 83.7 (83.4-83.9) 0.509 
 one yr 55 82.5 (78.8-86.2)  13,384 90.7 (90.4-90.9) < 0.001 
  two yrs 39 85.9 (81.4-90.3)  11,800 90.8 (90.5-91.0) 0.030 
KOOS Sport/Rec pre-op 68 39.7 (33.2-46.1)  17,543 41.2 (40.8-41.6) 0.641 
 one yr 55 49.8 (42.4-57.2)  13,385 63.2 (62.8-63.7) < 0.001 
  two yrs 39 55.3 (46.6-64.1)  11,799 64.3 (63.8-64.8) 0.046 
KOOS QoL pre-op 68 33.6 (29.1-38.1)  17,542 33.6 (33.3-33.9) 0.999 
 one yr 55 45.3 (38.8-51.8)  13,387 57.9 (57.5-58.4) < 0.001 
  two yrs 39 51.9 (44.2-59.6)  11,800 59.6 (59.1-60.0) 0.051 
EQ5D Index pre-op 65 0.66 (0.60-0.72)  16,442 0.68 (0.67-0.68) 0.687 
 one yr 51 0.67 (0.61-0.73)  12,895 0.79 (0.78-0.79) < 0.001 
  two yrs 38 0.79 (0.72-0.85)  11,359 0.80 (0.80-0.80) 0.641 
EQ5D VAS pre-op 64 60.2 (54.5-65.9)  16,262 62.7 (62.4-63.1) 0.385 
 one yr 53 63.9 (58.4-69.3)  12,805 75.1 (74.8-75.5) < 0.001 
  two yrs 38 71.1 (64.7-77.5)  11,489 76.0 (75.6-76.3) 0.139 
VTE, venous thromboembolism; CI, confidence interval; ADL, activity of daily living; Sport/rec, sport and recreational function; QoL, 





Table 13a. Demographic and clinical characteristics of patients 
with (n=291) and without (n=25,018) septic arthritis. 
 Septic Arthritis  
Variable, (incidence of SA) Yes No p-value 
Sex  total n 25,309  
 Woman, (0.8%) n (%) 91 (31.3) 10,697 (42.8) <0.001 
 Man, (1.4%) n (%) 200 (68.7) 14,321 (57.2)  
Age at surgery  total n 25,309  
 in years M (range) 27.2 (11-53) 26.8 (7-67) 0.556 
Body Mass Index, BMI  total n 11,904  
    M (SD) 25.4 (3.94) 24.5 (3.52) 0.003 
 Normal weight (BMI<25), (0.9%) n (%) 71 (54.6) 7425 (63.1) 0.132 
 Overweight (BMI 25-30), (1.4%) n (%) 53 (40.8) 3857 (32.8)  
 Obese (BMI >30), (1.2%) n (%) 6 (4.6) 483 (4.1)  
Smoking total n 12,169  
 Yes, (0.8%) n (%) 6 (4.5) 713 (5.9) 0.504 
 No, (1.1%) n (%) 126 (95.5) 11,324 (94.1)  
Diabetes Mellitus total n 25,309  
 Yes, (1.1%) n (%) 2 (0.7) 187 (0.7) >0.999 
 No, (1.2%) n (%) 289 (99.3) 24, 831 (99.3)  
VTE   total n 25,309  
 Yes, (4.4%) n (%) 4 (1.4) 87 (0.3) 0.021 
 No, (1.1%) n (%) 287 (98.6) 24,391 (99.7)  





















Figure 15. The improvement of EQ-5D from preoperatively to two-year follow-up presented for each subscale 
for respondents and late-respondents. Data adjusted for age at surgery and sex. 









Table 13b. Perioperative data of patients with (n= 291)  
and without (n= 25,018) septic arthritis. 
 Septic Arthritis  
Variable, (incidence of SA) Yes No p-value 
Type of surgery  total n 25,309  
 Outpatient surgery, (1.2%) n (%) 232 (79.7) 19,130 (76.5) 0.192 
 Inpatient surgery, (1.0%) n (%) 59 (20.3) 5888 (23.5)  
Type of surgery  total n 25,309  
 Primary, (1.2%) n (%) 276 (94.8) 23,622 (94.4) 0.753 
 Revision, (1.1%) n (%) 15 (5.2) 1396 (5.6)  
Cartilage lesion  total n 25,309  
 Yes, (1.4%) n (%) 99 (34.0) 6780 (27.1) 0.008 
 No, (1.0%) n (%) 192 (66.0) 18,238 (72.9)  
Meniscal suture  total n 25,309  
 Yes, (1.2%) n (%) 7.2 (21.0) 1668 (6.7) 0.709 
 No, (1.1%) n (%) 270 (92.8) 23,350 (93.3)  
Choice of graft  total n 25,309  
 Hamstring tendon, (1.2%) n (%) 280 (96.2) 23,083 (92.3) 0.012 
 Patellar tendon, (0.6%) n (%) 11 (3.8) 1935 (7.7)  
Operating time in min total n 23,919  
  M (Range) 82.0 (35-246) 74.5 (17-304) <0.001 
 <70 min, (0.8%) n (%) 84 (30.4) 10,631 (45.0) <0.001 
 ≥70 min, (1.5%) n (%) 192 (69.6) 13,012 (55.0)  
Perioperative antibiotic  total n 24,744  
 Cloxacillin, (1.1%) n (%) 272 (94.8) 23,861 (97.6) 0.002 
 Clindamycin, (2.5%) n (%) 15 (5.2) 596 (2.4)  
Perioperative antibiotic, dose total n 25,309  
 1 dose, (1.2%) n (%) 193 (66.3) 16,280 (65.1) 0.657 
 2 or more doses, (1.1%) n (%) 98 (33.7) 8738 (34.9)  
Prolonged antibiotic prophylaxis total n 25,309  
 Yes, (0.7%) n (%) 12 (4.1) 1638 (6.5) 0.101 
 No, (1.2%) n (%) 279 (95.9) 23,392 (93.5)  
M, mean    
 
Table 14. Anticoagulants used for definition of VTE. 
Generic name ATC code Minimum daily dosage 
Dalteparin B01AB04 10,000 IU 
Enoxaparin B01AB05 8000 IU 
Rivaroxiban B01AF01 30 mg 
Tinzaparin B01AB10 8000 IU 
Warfarin B01AA03 - 
 ATC, Anatomic Therapeutic Chemical; IU, International Unit 
 
